呼吸器感染症におけるCefoxitinの臨床的検討

桑原 正雄; 小泊 好幸; 城 智彦; 倉岡 敏彦; 光山 豊文; 小泊 直美; 岩本 恵子; 宮沢 輝臣; 渡辺 隆; 森川 英治; 粟屋 幸一; 沢井 洋征; 高見 京子; 山木戸 道郎; 西本 幸男

doi:10.11553/antibiotics1968b.37.1685

CLINICAL STUDIES ON CEFOXITIN IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

MASAO KUWABARA, YOSHIYUKI KODOMARI, TOMOHIKO JYO, TOSHIHIKO KURAOKA, TOYOFUMI MITSUYAMA, NAOMI KODOMARI, KEIKO IWAMOTO, TERUOMI MIYAZAWA, TAKASHI WATANABE, EIJI MORIKAWA, KOICHI AWAYA, HIROYUKI SAWAI, KYOKO TAKAMI, MICHIO YAMAKIDO, YUKIO NISHIMOTO

Author information

MASAO KUWABARA
Department of Internal Medicine, Hiroshima Prefectural Hospital
YOSHIYUKI KODOMARI
Department of Internal Medicine, Hiroshima Prefectural Hospital
TOMOHIKO JYO
Department of Internal Medicine, Hiroshima Prefectural Hospital
TOSHIHIKO KURAOKA
Department of Internal Medicine, Yoshijima Hospital
TOYOFUMI MITSUYAMA
Department of Internal Medicine, Koseiren Hiroshima Sogo Hospital
NAOMI KODOMARI
Department of Internal Medicine, Hataga National Hospital
KEIKO IWAMOTO
Department of Internal Medicine, Toyo Hospital
TERUOMI MIYAZAWA
Department of Internal Medicine, Hiroshima Municipal Hospital
TAKASHI WATANABE
Department of Internal Medicine, Oda National Hospital
EIJI MORIKAWA
Department of Internal Medicine, Otake National Hospital
KOICHI AWAYA
Department of Internal Medicine, Otake National Hospital
HIROYUKI SAWAI
Department of Internal Medicine, Hiroshima JNR Hospital
KYOKO TAKAMI
Department of Internal Medicine, Fukushima Seikyo Hospital
MICHIO YAMAKIDO
The Second Department of Internal Medicine, School of Medicine, Hiroshima University
YUKIO NISHIMOTO
The Second Department of Internal Medicine, School of Medicine, Hiroshima University

JOURNAL FREE ACCESS

1984 Volume 37 Issue 9 Pages 1685-1693

DOI https://doi.org/10.11553/antibiotics1968b.37.1685

Details

Abstract

The clinical effects of cefoxitin (CFX) were studied in 31 cases of respiratory tract infections.
The results were as follows:
1. As for the clinical effects, CFX was excellent in 5 cases, good in 13, fair in 8 and poor in 5 out of 31 patients; the efficacy rate was 58.1%.
2. The efficacy rate was 57.1% in bronchopneumonia, 61.1% in pneumonia and 50.0% in acute exacerbation of chronic respiratory tract infections.
3. The efficacy rate was 70.6% in the group of 4g/day or less and 42.9% in the group of 6g/day or more.
4. The efficacy rate was 50.0% in 6 cases that had not been responded to other antibiotics previously.
5. As for side effects, skin eruption was observed in only 1 patient.
6. No abnormality was observed in laboratory tests due to CFX.
7. In conclusion, CFX is a useful drug in the treatment of respiratory tract infections.

Corresponding author

Register with J-STAGE for free!